



## Noxopharm joins global Alliance for mRNA Medicines

### Highlights

- Company joins select group of mRNA industry pioneers
- Leading international advocacy organization
- US\$137 billion mRNA market by 2032

**Sydney, 28 May 2024:** Innovative biotech company **Noxopharm Limited (ASX:NOX)** announces it has joined the Alliance for mRNA Medicines (AMM) – the leading global organization dedicated to advancing and advocating for mRNA and next-generation encoding RNA therapeutics and vaccines.

AMM's mission is to propel the future of mRNA medicine, improve patients' lives, and advance scientific knowledge by convening and empowering mRNA industry leaders, innovators, scientists, and other key stakeholders.

In becoming a member, Noxopharm connects with a group of [industry leaders](#) that are pioneering mRNA and other RNA technologies on the global stage, and strengthens its position as one of the few Australian companies driving innovation in this area.

Membership also represents a key part of Noxopharm's strategy to further build and promote its Sofra technology platform, which contains cutting-edge assets such as its [SOF-VAC™](#) mRNA vaccine enhancer and [SOF-SKN™](#) lupus medication.

Interest in mRNA technology has grown exponentially following its central role in the success of major COVID-19 vaccines and has the potential to create much-needed new drugs and other vaccines for numerous diseases.

According to Precedence Research, the [mRNA market](#) in 2022 was US\$40 billion, and is expected to reach US\$137 billion by 2032 at a compound annual growth rate of 13%.

Noxopharm will actively participate in various AMM initiatives across its operations, including in crucial areas such as the development of new regulatory frameworks, as well as knowledge sharing and R&D. A deeper understanding of the evolving regulatory landscape will help the company operationally as it moves to bring its Sofra assets to the clinic and patients.

AMM's Executive Director, Clay Alspach, said: "We are delighted to welcome Noxopharm into the Alliance and believe that the team can make a real contribution to our organisation, especially in the Asia Pacific region. Noxopharm's groundbreaking work offers an attractive addition to the wide range of new and emerging technologies represented by our members."



Noxopharm CEO Dr Gisela Mautner said: “AMM is driving the promotion of mRNA-related technologies both in the US and around the world, and advancing policies and regulatory solutions that will allow our industry to grow rapidly and fulfil its promise. We are very pleased to join this illustrious group and look forward to playing our part to help shape our collective future.”

**-ENDS-**

### **About Noxopharm**

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance mRNA vaccines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Chroma™ (oncology) and Sofra™ (inflammation, autoimmunity, and mRNA vaccine enhancement).

Noxopharm also has a major shareholding in US registered, Australia based Nyrada Inc (ASX: NYR), a drug discovery and development company specialising in novel small molecule therapies.

To learn more, please visit: [noxopharm.com](http://noxopharm.com)

**Investor, Corporate & Media enquiries:**

Julian Elliott

M: 0425 840 071

E: [julian.elliott@noxopharm.com](mailto:julian.elliott@noxopharm.com)

**Company Secretary:**

David Franks

T: +61 2 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

*Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.*

---

### **Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.